tyb
>>7362549 pb Novartis nears deal to buy U.S. biotech firm Medicines Co for about $7 billion
Following up on the above:
Deals of this size ($7b) are not done in a week or a month, they habben over the period of a year or moar. Alex Denner sits on the BOD at Medicines Company and has been steadily buying shares since Dec '18. He will have had information privy to this sale to Novartis.
It's one thing to add a few shares here and there...but $58m of them when these discussions were going on? Total cronyism. Sarissa already has a large stake in Medicines Company and it's rumored sale price to Novartis is $85/sh. On top of the 2.6% of Medicines Co. Sarissa already owned when the BOD was restructured to place his people on it they began adding LARGE at around $20/sh in Dec. '18. Do the math.
The company 's main competitors are Amgen and Regeneron(Sanofi) with cholesterol dugs.
Sarissa Capital restructured the BOD in March 2018 from 12 to 7 members. Half of those are associated with Sarissa. Denner (the buyer of these shares) is tied to Carl Icahn and the past sales of Bioverativ and Ariad Pharmaceuticals were orchestarted by Denner. Denner split with Icahn in 2012 to form Sarissa. Sarissa also holds stakes in AbbVie, Biogen and Innoviva, among other drug companies
In January 2017, Denner (Sarissa)orchestrated the sale of biotech company Ariad to Japanese drugmaker Takeda, for $5.2 billion. Panayiotopoulos was CEO of Ariad and Schlesinger was a director-these are two of the BOD members nominated and confirmed at Medicines Co in 2018. . Denner helped facilitate the sale of hemophilia drug maker Bioverativ, for $11.6 billion, to Sanofi in January 2018
Sarissa is a Greek word. The sarissa or sarisa was a 4 to 7 meter long spear used in the ancient Greek and Hellenistic warfare. It was introduced by Philip II of Macedon and was used in the traditional phalanxes of Philip II of Macedon as a replacement for the earlier dory, which was considerably shorter.
https://www.businessinsider.com/r-sanofi-confirms-deal-to-buy-bioverativ-for-116-billion-2018-1
https://www.cnbc.com/2018/03/01/activist-alex-denner-to-gain-board-control-at-medicines-company.html
https://www.forbes.com/sites/antoinegara/2017/01/09/ariads-5-2-billion-sale-to-takeda-nets-260-million-windfall-for-hedge-fund/#70b4e2ea773f
sauce for panel
scroll down
https://www.finviz.com/quote.ashx?t=MDCO
Bloomberg News Announces It Will No Longer Investigate Any Of Mike Bloomberg's Democratic Rivals
What happens when a billionaire finance and media mogul announces he is running for president? How does his media empire avoid running into countless conflicts of interest? Well, in the case of Bloomberg News, which is the sole domain of Michael Bloomberg who just officially entered the 2020 presidential race, the company's editor-in-chief just announced that it will extend its long-running policy of not doing any investigative reporting on its owner to all of his Democratic competitors who are also running for president.
Or, as Bloomberg editor-in-chief John Micklethwait said, "We cannot treat Mike's Democratic competitors differently from him."
And that's why handing America's free media into the hands of a handful of organizations and a few billionaires is generally a bad idea, because sooner or later one or all of them decide that the world will be better if they run it, and the conflicts of interest explode, which means far less coverage of precisely those who need the most investigation at precisely the most important time - just when they are about to be elected president.
On the other hand, while Bloomberg News will no longer cover any of the potential Democratic presidents, period, its "P&I team will continue to investigate the Trump administration, as the government of the day", albeit with the running disclaimer that its boss sees himself as Trump's biggest challenger. Good luck with objective reporting there.
What happens in the odd chance that Mike Bloomberg does win the nomination, at which point the billionaire will effectively have a massive "objective" newsroom as a PR weapon? According to Bloomberg News, it is still determining if and how it will continue to investigate the Trump administration if Bloomberg were to win the Democratic nomination and run against Trump in the general election. Until then, however, Bloomberg will clearly continue to focus on the president who for better or worse, remains the biggest traffic draw not only for Bloomberg but for every other media outlet out there.
All this was revealed in a memo to Bloomberg employees sent on Sunday morning after Bloomberg officially announced his candidacy, in which editor-in-chief John Micklethwait said also that:
-Going forward, the company will disclose that Bloomberg owns the company in all of its stories about the election.
-If other outlets publish stories about Bloomberg, Bloomberg Media would "either publish those articles in full, or summarize them for our readers - and we will not hide them."
-He noted that the company is following the same policy that it has applied to its coverage of corporate rivals CNBC and Reuters. Bloomberg doesn't investigate those companies, but it does report on the news of the day if it involves them.
-He said that Bloomberg News has already assigned a reporter to follow Bloomberg's presidential campaign, just as the company did when Bloomberg was running for New York City mayor.
-Bloomberg News would suspend its editorial board and that David Shipley, Tim O'Brien and other editorial board members will take a leave of absence to join Bloomberg's presidential campaign. Opinion columnists will continue to produce pieces, but editorial board bylines will cease.
rest at link
https://www.zerohedge.com/economics/bloomberg-news-announces-it-will-no-longer-investigate-any-mike-bloombergs-democratic
sure nigga so I can be put in the same boat as the newsfag. STFU. do it how I want.
(13)